ERBB2 and breast carcinoma: In the second-line setting for trastuzumab-treated HER2-positive advanced breast cancer, with respect to PFS (#1) benefit, pyrotinib + capecitabine had the highest probability of ranking first (SUCRA = 0.972), followed by T-DM1 + atezolizumab (SUCRA = 0.810), pertuzumab + trastuzumab + capecitabine (SUCRA = 0.665), and T-DM1 (SUCRA = 0.649).